Can a breast cancer combo be safer for diabetics?

NCT ID NCT07748208

Not yet recruiting Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial is testing whether a combination of drugs—inavolisib plus fulvestrant, with or without palbociclib—is safe for people with a specific type of advanced breast cancer (HR+, HER2-negative) that has a PIK3CA mutation, and who also have type 2 diabetes. The main focus is on how the treatment affects blood sugar levels, particularly the risk of severe high blood sugar. About 40 participants will receive the treatment, and researchers will monitor for side effects and hospitalizations related to blood sugar issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inavolisib combined with fulvestrant, with or without palbociclib
What this could lead to: If successful, this could provide a safer treatment option for people with advanced breast cancer who also have type 2 diabetes, potentially reducing the risk of severe high blood sugar.
What could go wrong: This is a small, early-phase study focused on safety, not effectiveness. The combination may still cause significant blood sugar issues or other side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER DIABETES TYPE II

More trials for these conditions

Other studies related to the condition(s) this trial covers.